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REPLACR-mutagenesis, a one-
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Mutagenesis is an important tool to study gene regulation, model disease-causing mutations and for 
functional characterisation of proteins. Most of the current methods for mutagenesis involve multiple 
step procedures. One of the most accurate methods for genetically altering DNA is recombineering, 
which uses bacteria expressing viral recombination proteins. Recently, the use of in vitro seamless 
assembly systems using purified enzymes for multiple-fragment cloning as well as mutagenesis 
is gaining ground. Although these in vitro isothermal reactions are useful when cloning multiple 
fragments, for site-directed mutagenesis it is unnecessary. Moreover, the use of purified enzymes 
in vitro is not only expensive but also more inaccurate than the high-fidelity recombination inside 
bacteria. Here we present a single-step method, named REPLACR-mutagenesis (Recombineering of 
Ends of linearised PLAsmids after PCR), for creating mutations (deletions, substitutions and additions) 
in plasmids by in vivo recombineering. REPLACR-mutagenesis only involves transformation of PCR 
products in bacteria expressing Red/ET recombineering proteins. Modifications in a variety of plasmids 
up to bacterial artificial chromosomes (BACs; 144 kb deletion) have been achieved by this method. The 
presented method is more robust, involves fewer steps and is cost-efficient.
Site-directed mutagenesis (SDM), also known as directed mutagenesis, is used to generate mutations, add or 
delete domains in cDNAs or gene promoters in order to study the resulting translation product for protein engi-
neering and/or functional characterisation. SDM is also used to model mutations found in clinical samples for 
functional studies at the cellular and molecular level.
There are a vast number of techniques and commercial kits to generate point mutations, short additions or 
deletions, mainly based on PCR such as overlap extension and megaprimer PCR1–7. Yet most involve several steps 
and are limited by the size of insertion or deletion due to the use of complementary primer pairs. In most cases, 
mutagenesis is accompanied with ligation of the resulting linear PCR fragment to form a circular vector, which is 
inefficient and can result in unwanted additions or deletions due to the activities of the polymerase used.
Homologous recombination (HR) is a process where a pair of homologous DNA fragments exchanges nucle-
otides, often as means to repair DNA breaks. HR was first used to modify genetic material in yeast8. Later on, 
the bacteriophage enzymes that perform HR independently of the bacterial system were discovered and used 
to modify plasmids, bacterial artificial chromosomes (BACs), and bacterial genomes9–12, a method now called 
recombineering (recombination-mediated genetic engineering)13. These enzymes allow genetic modifications by 
recognising complementary DNA strands for strand invasion or annealing14,15. One limitation for this seamless 
cloning technique is the need of selection of positive clones, something we, among many others, have solved by 
using selection/counter-selection systems16–19.
Recently, a series of methods based on the assembly of overlapping DNA fragments using in vitro reactions 
have been developed, such as Gibson assembly20, GeneArt seamless cloning (Life technologies), In-Fusion HD 
cloning (Clontech), ligase-independent cloning (LIC) and the variations of the latter (SLIC and SLICE)21–23. These 
in vitro methods can join several fragments of DNA with 15–25 nucleotide homology at both termini. Yet, there 
are limitations for these assemblies such as single-stranded DNA secondary structures and cloning of primer 
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dimers24. A common feature of these methods is the use of purified DNA-modifying enzymes (exonucleases, 
recombinases, polymerases and ligases), which not only makes these methods highly expensive but also depend-
ent on selective buffers and reaction conditions. In addition, in vitro DNA termini-joining can also yield many 
non-specific products, which is in stark contrast to in vivo recombineering that is highly selective and robust due 
to the presence of endogenous proofreading replication and repair pathways.
Although in vitro methods are highly advantageous for multiple fragment cloning, they are, however, com-
pletely unnecessary for generating mutations at a single locus (substitutions, additions or deletions) in plasmids. 
Here we present a single-step method where, by in vivo recombineering, we are able to generate site-directed 
modifications (point mutations, deletions, additions and substitutions) in plasmid vectors in a cost-effective man-
ner with high efficiency and accuracy. Since the method is primarily focused on generating mutations in plasmids 
and the only step needed is PCR followed by recombineering of the linearised ends of the plasmid, we named the 
method as REPLACR-mutagenesis (Recombineering of Ends of linearised PLAsmids after PCR; Fig. 1).
Results
Optimal homology for REPLACR-mutagenesis. We rationalised that the linear ends of a PCR product 
could be circularised by recombineering if they had enough homology. Thus, we first amplified a plasmid by PCR 
such that the resulting linear PCR products had a varying number of homologous nucleotides at their ends. To 
determine the optimal length of homology needed for highest recombination efficiency, we tested 23 bp primer 
pairs with homology ranging from 2 bp to 23 bp (See Supplementary Table S1 for primer sequences). The primers 
targeted a ScaI restriction site (AGTACT) in the wild-type (WT) human luteinizing hormone/chorionic gonado-
tropin receptor (LHCGR) plasmid25 by the addition of two nucleotides (AT) in the middle of a ScaI sequence, such 
that the resulting site in the plasmid was not amenable to ScaI digestion. The number of correct clones found over 
the LHCGR_WT background was used to calculate the efficiency with respect to the homology at the ends of the 
PCR products (Fig. 2a). A 2 bp homology at the ends of PCR products is insufficient for recombination, thereby 
resulting in no positive clones. From 5 bp homology onwards, there was an increase in efficiency of REPLACR-
mutagenesis up to 17 bp, with the maximum efficiency of 84%. Since the primers were only 23 bp long, a 20 bp 
and 23 bp homology among the primers favoured the formation of primer dimers thereby resulting in undesired 
PCR products. The bacterial colonies containing either the mutated plasmids or LHCGR_WT background were 
screened by colony PCR and subsequent ScaI restriction digestion of the PCR products. Supplementary Figure S1 
shows the ScaI restriction digestion patterns of PCR products obtained for one representative experiment, and the 
results are summarised in Supplementary Table S2, detailing the number of colonies obtained, screened, correct 
ones found and the associated efficiencies. The colony PCR conditions are mentioned in Supplementary Table S3.
Using oligonucleotides that span 22–24 nucleotides of primer-template binding plus a 5′ -tail containing the 
homology arms can further increase the total length of the homology. As mentioned later in the manuscript, 
different mutants were made where longer primers with more more than 17 bp homology (20, 23 and 30 bp 
homology) were used, however, the associated efficiencies were very similar to the 84% efficiency as achieved by 
17 bp homology (See Supplementary Figure S2). Thus, a 17 bp homology with 3′ overhangs for both primers is 
sufficient for efficient REPLACR-mutagenesis.
In addition, when three PCR products with 11 bp, 14 bp and 17 bp homology were transformed in 
non-recombineering bacteria (E.coli DH-10β ), no colonies were obtained because linear PCR products cannot 
recombine own their own in the absence of enzymes needed for recombination.
Efficiency comparison with commercial kits (Gibson Assembly and GeneArt seamless clon-
ing). Since the PCR products with 14 bp and 17 bp homology at their termini gave highest efficiencies with 
REPLACR-mutagenesis (Fig. 2a), we used the same PCR products with two commercially available kits, namely 
Gibson assembly and GeneArt seamless cloning. The efficiencies of the Gibson assembly and GeneArt seamless 
cloning were similarly determined by ScaI digestion of the colony PCR products (see Supplementary Fig. S3). 
Although PCR products with 14 bp homology gave higher efficiencies with Gibson assembly and GeneArt, but 
for PCR products with recommended 17 bp homology, efficiencies all the methods were comparable (Fig. 2b). 
Moreover, we consistently found GeneArt cloning to result in smaller number of overall colonies as compared 
with REPLACR-mutagenesis or Gibson Assembly (see Supplementary Table S4).
Substitutions. All substitutions were targeted to plasmids encoding the human LHCGR, follicle-stimulating 
hormone receptor (FSHR) or beta-2 adrenergic receptor (β2AR). We generated many single nucleotide substitu-
tions, namely, LHCGR_Asn291Ser, LHCGR_Val454Ile, FSHR_Ala444Thr, FSHR_ Gly70Ala, β 2AR_Asp79Asn, 
β 2AR_Asp130Asn and β 2AR_Cys341Gly and a double nucleotide substitution, β 2AR_Tyr350Ala (See 
Supplementary Figure S4). The primers used for creating substitutions and verifying via DNA sequencing are 
mentioned in Supplementary Tables S5 and S6, respectively.
Deletions. Because the method is not limited to point substitutions, we also tested whether we could delete 
nucleotides. First, we deleted a single nucleotide in the LHCGR (1850delG), which results in a frame-shift of 
the C-terminal tail of the receptor; the functional tests for this mutant receptor have been reported elsewhere26. 
This deletion was achieved as verified by sequencing (see Supplementary Figure S5). As deletion of a nucleotide 
worked as efficiently as nucleotide substitutions, we proceeded to generate larger editing of the DNA sequence of 
some plasmids.
The deletion of 12 nucleotides of the signal peptide of the LHCGR gene (LHCGR-Lys12-Leu15del) was 
achieved using the same method. Once again, we produced hundreds of colonies where most of them were cor-
rect as verified by sequencing (see Supplementary Figure S5).
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Finally, we used REPLACR-mutagenesis to delete an entire 144 kb DNA sequence from a human LHCGR BAC 
clone (RPCI-11-186L7), a one step “BAC-shaving” as compared with the multistep systems to-date27. The primer 
sequences used for the deletion are mentioned in Supplementary Table S5. The resulting deletion was verified by 
sequencing (Supplementary Fig. S5). The primers used for sequencing are specified in Supplementary Table S6. PCR 
conditions for deletion are mentioned in Supplementary Table S7. In addition, since the chloramphenicol resistance 
gene and origin of replication were not affected during PCR, the resulting plasmid could propagate in chloramphen-
icol containing Luria-Bertani (LB) medium, demonstrating the integrity of the backbone during PCR.
Figure 1. Principle of REPLACR-mutagenesis and primer design strategy for sequence substitution, 
addition or deletion. (a) Primers containing the desired mutation are designed to target a specific region in 
the original vector. A high-fidelity polymerase is used to generate a linear PCR product such that both the ends 
contain overlapping sequences for recombination. Bacteria expressing the recombineering proteins (Redγ , β , 
α and RecA) are transformed with the PCR product. Recombination takes places inside the bacteria thereby 
yielding a circular plasmid containing the desired mutation. Bacterial colonies are then screened for the correct 
clone by PCR and sequencing. (b) Forward and reverse primers contain the desired addition/substitution as 
a part of homology regions needed for recombination, besides containing a 3′ extension for effective template 
binding. The homology region (17 bp or more) for substitutions also contains the desired nucleotide change.  
(c) For generating deletion mutants, forward primer contains the sequence adjoining the sequence to be deleted. 
The reverse primer however contains a sequence homologous to the forward primer and the adjoining sequence 
in the vector.
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Additions. In order to generate mutants with additional nucleotides, the LHCGR_Leu10-Gln17Dup, a 
27-nucleotide duplication, was generated. This construct produced many colonies but most of them were nega-
tive, probably due to a preference for near-end recombination and the presence of 2 identical sequences (dupli-
cation). The correct colonies were obtained by generating forward and reverse strands separately in two separate 
PCR reactions and thereafter the two products were mixed together. The PCR products were heated up to 95 °C 
and slowly allowed to cool for annealing of DNA strands, followed by DpnI digestion before transformation in 
Red/ET bacteria, as previously described28. The sequence was verified by sequencing (Supplementary Figure S6). 
Neither Gibson assembly nor GeneArt produced any correct colonies for this duplication.
In order to show that there is no limit on the number of additional nucleotides to be incorporated as far 
as they have homology arms, we inserted a 45-nucleotide nuclear localization signal to a plasmid containing 
Cryptochrome Circadian Clock 2 (CRY2) gene29. Moreover, a 60-nucleotide addition of a flexible domain was 
also achieved using REPLACR-mutagenesis (Supplementary Figure S6). The primer sequences used to generate 
the mutations are mentioned in Supplementary Tables S5. The sequencing primers used to verify the additions 
of 45 and 60 nucleotides were TTGCTCGTTGGCATCAGAAGG and AGCTGCTGCTAATGCAGGAT, respec-
tively. We did not try longer additions as the cost for larger primers become higher than using synthetic DNA 
“blocks” and Gibson assembly.
Modifications of larger plasmids. A 24 kb Wnt1 targeting vector was used to introduce a 2 bp addition. 
The two bases (TG) were introduced in one the three MfeI restriction sites (CAATTG) present in the origi-
nal vector such that the resulting sequence (CAATGTTG) leaves only two MfeI restriction sites in the mutated 
plasmid. MfeI restriction digestion of the original Wnt1 vector with three MfeI restriction sites results in three 
bands (15476, 6379, 1844 bp; lane 2 in Fig. 3) whereas the modified Wnt1 vector with a mutated MfeI site results 
in two bands (15476 and 8225 bp; lane 4 in Fig. 3), as expected. The mutated region was verified by sequencing 
(Supplementary Figure S7). The primers for creating the mutation and sequence verification by DNA sequencing 
are stated in Supplementary Tables S5 and S6, respectively. The PCR conditions are mentioned in Supplementary 
Table S8. The mutated plasmid could replicate in kanamycin conditioned LB-agar plates, similar to the original 
plasmid, demonstrating the integrity of the antibiotic resistance gene as well as the origin of replication. Overall, 
the sequencing of the mutated site, the expected restriction digestion pattern and the ability of the plasmid to 
propagate in bacteria cultured in the appropriate antibiotic containing medium demonstrates the integrity of a 
larger and complex plasmid mutated with REPLACR-mutagenesis.
Modifying plasmid with similar incompatibility to the recombineering plasmid. A potential 
limitation of REPLACR-mutagenesis could be the modification of plasmids with origin of replication incom-
patible with the Red/ET plasmid (pSC101). To test this, recombineering bacteria were prepared with Red/ET 
plasmid carrying tetracycline resistance gene. We have previously modified a similar Red/ET plasmid (pSC101 
BADgbaRecA) containing hygromycin rather than tetracycline resistance gene16. A fragment of the temperature 
sensitive repressor (RepA) was deleted (944 bp) and was verified by sequencing (Supplementary Figure S8). The 
primers for mutagenesis, sequencing and the PCR conditions are specified in Supplementary Tables S5, S6 and S9, 
respectively. The original plasmid can only be grown at 30 °C due to active repressor while the mutated plasmid 
with an inactive repressor could now be grown at 37 °C. This shows the utility of the REPLACR-mutagenesis to 
Figure 2. Efficiency of REPLACR-mutagenesis. (a) The effect of homology at the ends of PCR products is 
plotted against the achieved efficiencies with REPLACR-mutagenesis. The efficiency of mutagenesis increases 
with increasing homology, where a 2 bp homology is insufficient to yield any correct products while a 17 bp 
homology gives the highest efficiency at 84%. (b) The same PCR products with 14 bp and 17 bp homology were 
used with two commercial kits (Gibson Assembly and GeneArt Seamless cloning) and the achieved efficiencies 
were compared with REPLACR-mutagenesis. REPLACR-mutagenesis is least efficient among the three methods 
when the PCR products have only 14 bp homology, however with the recommended 17 bp homology at the 
ends of PCR products, comparable efficiencies for all the methods can be observed. The data is presented as 
mean ± standard error of mean (SEM) of three independent repeats.
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modify plasmids with similar incompatibility to the recombineering plasmid. This is possible because the electro-
competent bacteria are already expressing the recombination enzymes during their preparation and the original 
recombineering plasmid cannot replicate at 37 °C, thereby eliminating any selective pressure. However, we found 
very few colonies after REPLACR-mutagenesis and the recombination efficiency of 33% as only one out three col-
onies were positive. This suggests that the incompatibility of the origins of replication has a negative effect, which 
result in low efficiencies, but it is possible to achieve mutations even in such circumstances.
Discussion
REPLACR-mutagenesis presents a quick and robust in vivo recombineering based mutagenesis protocol. The 
only step needed is the transformation of PCR products in bacteria expressing viral recombination proteins. An 
effective primer design is thus crucial for this method. The general primer design strategy, specific for additions, 
deletions and substitutions is summarised in Fig. 1. Primers should be designed such that the resulting PCR 
products contain a homology at their termini of around 17bp. As seen in Fig. 2a, a 17 bp homology at the ends 
of PCR products gave the highest efficiency of 84% over the background. For 23 bp primer pairs, up to 17 bp 
homology (with 6 additional nucleotides at 3′ end) resulted in expected PCR products whereas a 20 bp and 
23 bp homology among primers resulted in undesired PCR products. Therefore, besides containing the homology 
regions, the primers should include a 3′ extension (6 nucleotides or more), such that primer-template binding is 
favoured over primer-primer self-complementarity. For creating substitutions, the homology region also contains 
the substituted nucleotide(s), with an extended 3′ end. For additions, a 20 bp region for primer template binding 
is sufficient and the additions can be made on the 5′ end of either one or both primers. The added regions should 
contain a 17 bp homology for maximum efficiency. However, for creating deletions, one of the primers should 
contain the adjoining sequences between the region to be deleted and the other primer containing a 17 bp homol-
ogy to the 5′ end of the first primer and an additional 3′ sequence in the other direction. It is however possible 
to design longer primers, with more than 17 bp homology but there is no significant increase in efficiency (see 
Supplementary Figure S2). In addition, longer primers also increase the cost as well as the chances of formation 
of secondary structures, thereby decreasing the PCR efficiency in some cases.
The bacteria used for recombination contain Red/ET plasmid, which during their preparation are made to 
express viral recombination proteins under arabinose promoter, by addition of L-Arabinose and subsequently 
frozen until use. The replication of Red/ET plasmid is temperature sensitive and only replicates at 30 °C30. Thus, 
after transforming the PCR products, the bacteria are grown at 37 °C and the resulting bacterial colonies only 
contain the desired mutated plasmid and not the original Red/ET plasmid. In addition, it is also possible to 
modify plasmids with incompatibility as the Red/ET plasmid because the electrocompetent bacteria are already 
Figure 3. Modifications in larger plasmids. The 24 kb Wnt1 targeting vector (undigested; lane 1) contains 
three MfeI restriction sites, which upon MfeI digestion gives three bands (15476, 6379, 1844 bp; lane 2). One 
of the MfeI sites is mutated by REPLACR-mutagenesis, such that the resulting plasmid (lane 3) upon MfeI 
digestion gives only two bands (15476 and 8225 bp; lane 4).
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expressing the recombination proteins to circularise the PCR products. However, the plasmid to be mutated 
should have a different antibiotic resistance gene than the Red/ET plasmid.
The method was used to successfully generate a variety of point substitutions, deletions ranging from one 
nucleotide deletion to as large as 144 kb deletion (shaving) in human LHCGR BAC in one single step, which 
would otherwise require multiple steps via traditional restriction digestion based deletion techniques or those 
involving selection/counter-selection cassettes17,27,31,32. We were also able to add nucleotides ranging from one 
to 60 nucleotides. The limitation of adding nucleotides by longer primers is the cost of primers themselves. The 
method was thus used to generate mutations in small plasmids (6–10 kb) to as large as a 24 kb Wnt1 targeting 
vector.
Traditional PCR based mutagenesis methods typically require a variety of steps and the application of 
many enzymes such as kinases for phosphorylation of 3′ ends and ligases to form circular plasmids. Similarly, 
recombination-based mutagenesis and cloning methods (Gibson Assembly and GeneArt seamless cloning) also 
require the application of expensive enzymes and multiple steps. In both GeneArt and Gibson assembly, PCR of 
the template DNA is followed by DNA purification, in vitro recombination and subsequent transformation into 
bacteria. Our method reduces the number of steps needed for creating mutations to just one-step since the PCR 
product is directly transformed in the bacteria and there is no need for an additional in vitro incubation of PCR 
product with recombineering enzymes. In addition, it is considerably cheaper since the electrocompetent bacteria 
have to be prepared only once for a large number of mutagenesis experiments. Moreover, REPLACR-mutagenesis 
is as efficient as the commercially available Gibson assembly and GeneArt seamless cloning kits. Finally, a median 
efficiency of 75% was found for all the mutations made using our method (see Table 1).
The method bears similarity in primer design to PCR-based mutagenesis methods like quikchange 
site-directed mutagenesis (Agilent Technologies), where nicks in circular PCR products are repaired by bacterial 
endogenous DNA repair machinery7. However, most PCR products are linear and the number of circular PCR 
products with nicks that can be repaired by bacterial endogenous repair systems is very low, and henceforth 
the method becomes inefficient particularly for mutagenesis of more than one nucleotide. Thus, the expression 
of viral recombination proteins in bacteria as proposed in our method greatly enhances the efficiency of the 
recombination at the ends of linear PCR products as well as the number of bacterial colonies obtained. Moreover, 
REPLACR-mutagenesis is capable of complex additions and deletions in fewer steps than what would be needed 
by other PCR-based mutagenesis methods such as overlap extension PCR mutagenesis. Although there have been 
reports of using in vivo recombineering-based methods for mutagenesis in one single transformation step such as 
“en passant mutagenesis” but the bacterial colonies have to be grown and selected by colony PCR twice in different 
conditions, thereby prolonging the experiment33. The presented method however, involves direct screening of 
bacterial colonies obtained after the transformation step.
Although in the case of the large duplications we experienced problems during the PCR step, we solved it by 
generating single complementary strands of the vector and then re-joining them in an isothermal reaction, as 
previously described28, before transformation into Red/ET electrocompetent bacteria. The generation of com-
plimentary DNA strands using two PCR reactions with only one primer each is a known way to PCR the DNA 
regions with tandem repeats. One of the limiting factors in REPLACR-mutagenesis is the PCR itself; since most 
high-fidelity polymerases are recommended for PCR products up to 20–25 kb, though there have been some 
improvements in development of better polymerases. Nevertheless, most plasmids containing the cDNA of 







LHCGR_Asn291Ser 5 4 80
LHCGR_Val454Ile 5 5 100
FSHR_Ala444Thr 8 6 75
FSHR_Gly70Ala 8 5 63
β 2AR_Asp79Asn 5 1 20
β 2AR_Asp130Asn 5 4 80
β 2AR_Cys341Gly 5 1 20
β 2AR_Tyr350Ala 5 5 100
LHCGR_1850delG 8 7 88
LHCGR_Lys12-Leu15del 8 5 63
LHCGR_deletion_144kb (RPCI-11-186L7) 8 1 13
LHCGR_Leu10-Gln17Dup 16 2 13
CRY2_NLS (45 nt addition) 8 6 75
Flexible domain (60 nt addition) 8 6 75
Wnt1 targeting vector 8 4 50
Table 1.  The mutations in the plasmids were introduced by REPLACR-mutagenesis and were verified by 
DNA sequencing. The number of bacterial colonies screened and the number of correct mutations found over 
background were used to calculate the associated efficiencies. The median efficiency associated with all the 
mutations combined was 75%.
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In conclusion, REPLACR-mutagenesis provides a cost-effective way involving fewer steps to produce muta-
tions with high accuracy due to the nature of the Red/ET recombineering system.
Methods
Materials. KOD-Xtreme hot-start DNA polymerase was purchased from Merck Millipore. Three previ-
ously described plasmids carrying cDNA of the human LHCGR, FSHR and β2AR were used for all the substi-
tutions25,34,35. Restriction endonucleases DpnI and MfeI were purchased from New England Biolabs (NEB) and 
ScaI was purchased from Promega. Wnt1 targeting vector (24 kb) was purchased from the KOMP Repository 
(University of California Davis and Children’s Hospital Oakland Research Institute, USA). pCRY2FL(del-
taNLS)-mCherryN1 was a gift from Chandra Tucker (Addgene plasmid # 26871)29. The Red/ET plasmid, 
pSC101BADgbaRecA[tet], was purchased from Genebridges (Dresden, Germany).
Preparation of Electrocompetent bacteria for recombineering. Red/ET recombineering system (Red 
γ , β , α and RecA) containing recombineering plasmid (pSC101BADgbaRecA[tet]; hereafter called as Red/ET) 
was purchased from GeneBridges. Electrocompetent cells were prepared as described in the manuals from 
Genebridges using L-arabinose to induce the phage recombinases. Recombineering was performed in electro-
competent HS996 E.coli cells harbouring the Red/ET plasmid using standard recombination procedures14. Briefly, 
four microcentrifuge tubes with 1ml Luria-Bertani (LB) medium supplemented with either tetracycline (3 μ g/ml) 
or hygromycin (15 μ g/ml) were inoculated with bacteria harbouring the Red/ET plasmid and cultured over-
night at 30 °C in a table-top thermomixer (Eppendorf). Next day, the 4 ml bacterial culture was transferred to a 
250 ml LB culture with the appropriate antibiotic and was cultured for a further 3 h (250 rpm at 30 °C). Thereafter, 
L-arabinose was added to a final concentration of 0.35% and the temperature increased to 37 °C to induce the 
expression of the recombinases for 1 h. Bacteria were then collected by centrifugation 6000 X g for 15 min at 4 °C 
and were then resuspended in ice-cold water. This procedure was repeated once before resuspension in 10% glyc-
erol, followed by centrifugation as above and resuspension of the bacteria in the remaining 10% glycerol (about 
1 ml). Bacteria were then aliquoted into ice-cold microcentrifuge tubes (50 μ l per tube) and snap-frozen in liquid 
nitrogen before storage at − 80 °C until further use.
PCR. PCR primers were designed to generate addition(s), substitution(s) or deletion(s) of specific regions 
in the wild-type (WT) LHCGR, FSHR, β2AR or CRY2 plasmids25,29,35,36 (Fig. 1). Primer sequences specific 
for the mutation are listed in Supplementary Table S5. PCR was performed using a high-fidelity polymerase 
(KOD-Xtreme, Millipore) (see Supplementary Tables S7-S12 for PCR conditions). PCR products were purified 
by ethanol precipitation followed by DpnI digestion of the template plasmid. DpnI-digested PCR products were 
ethanol-precipitated and subsequently used for bacterial transformation. DpnI digestion can also be directly per-
formed on the PCR products (1–2 μ l) without purification and the DpnI digested products can then be trans-
formed in recombineering bacteria.
Site-directed mutagenesis. Mutagenesis involves only one-step: transformation of the PCR products gen-
erated using mutagenesis primers in recombineering bacteria (see Fig. 1 for principle and primer design).
Recombineering. For generating mutants, one tube of electrocompetent cells was used per sample. Cells 
were first thawed on ice and the PCR product (100 ng) was then added, followed by electroporation in a 1-mm 
cuvette. Electroporation was performed at 1.35 kV, 25 μ F, 200 ohms using an Eppendorf electroporator (2510). 
After electroporation, bacteria were incubated in 1 ml LB medium at 37 °C, shaking for 1–2 h before plating on 
LB-agar plates conditioned with the appropriate antibiotic(s).
Analysis of correct clones was performed first by PCR by primers flanking the targeted area using Biotools 
DNA polymerase and buffer. The general conditions included an initial denaturation at 96 °C for 2 min, fol-
lowed by 30 cycles with 95 °C for 45 s, 57 °C for 45 s and 72 °C for 1–3 min, depending on the length of the prod-
uct. Products were analysed by gel electrophoresis and then by sequencing (Turku Centre for Biotechnology, 
Finland). Sequencing was performed in both directions to ensure accuracy of the mutated modified sequences 
(See Supplementary Table S6 for sequencing primers).
Determining optimal homology length needed for REPLACR-mutagenesis. Primers were 
designed for the addition of two nucleotides (AT) in the middle of a ScaI restriction site (AGTACT) in WT 
human LHCGR plasmid, thereby disrupting the restriction site25. The homology between forward and reverse 
primers was varied from 2bp to 23 bp (See Supplementary Table S1 for primer sequences). PCR products 
were subjected to REPLACR-mutagenesis protocol as mentioned above (Fig. 1). The resulting bacterial col-
onies were analysed by colony PCR (forward primer: AGGGTCCTGATTTGGCTGAT, reverse primer: 
TGGCATGTCTTAATCGCAGC; see Supplementary Table S3 for PCR conditions). The expected PCR product 
for the mutated plasmids should be 366 bp and not amenable to ScaI digestion whereas the LHCGR_WT back-
ground PCR product should be 364 bp and following ScaI digestion to yield 190 bp and 174 bp products (indistin-
guishable as a single band; see Supplementary Fig. S1).
Gibson Assembly and GeneArt seamless cloning. The same PCR products with 14 bp and 17 bp homol-
ogy, as used above with REPLACR-mutagenesis, were subjected to recombination by Gibson Assembly cloning 
(NEB) and GeneArt seamless cloning (Life technologies) kits following the manufacturers’ protocol and using 
100 ng of the linear PCR product. The resulting bacterial colonies were subjected to colony PCR (Supplementary 
Table S3) and analysed by ScaI restriction digestion of the colony PCR products (see Supplementary Fig. S3 and 
Table S4).
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